Analysis of clinicopathological factors associated with bone metastasis in breast cancer

Objective: Bone is the most common site of metastasis in breast cancer. Prognostic factors for predicting bone metastases in breast cancer are controversial yet. In this study, we investigated clinical factors associated with secondary bone metastasis of breast cancer. Methods: In total, 1690 patients with breast cancer recorded between 2002 and 2012 in Motamed Cancer Institute, Tehran, Iran entered in the retrospective study. We studied age, menopausal status, histologic type, tumor size, number of cancerous axillary lymph nodes, serum concentrations of alkaline phosphatase (ALP), carcinogenicity antigen (CEA), cancer antigen (CA)-153, and hemoglobin (HB) in 2 groups with bone metastases (n = 123) and without it, respectively. We applied logistic regression to identify bone metastasis prognostic factors in breast cancer patients and calculated the cut-off value, sensitivity, and characteristics of independent prognostic factors using receiver operating characteristic (ROC) curve analysis. Results: Menopause, larger tumor size, and the greater number of cancerous axillary lymph nodes increased the chance of bone metastases significantly ( P < .05). There was no significant difference between mean groups with and without bone metastases regarding serum concentration of CEA, CA-153, HB, and histopathologic type ( P > .05). Logistic regression showed that age (odds ratio (OR) = 1.021), menopausal status (OR = 1.854), number of cancerous axillary lymph nodes (OR = 1.065), a tumor size between 2 and 5 cm diameter (OR = 2.002) and more than 5 cm diameter (OR = 4.009), and ALP (OR = 1.005) are independent prognostic factors associated with bone metastases. The ROC curve showed that the abovementioned factors have comparable predictive accuracy for bone metastases. Conclusions: Age, menopausal status, number of axillary lymph node metastases, tumor size, and ALP were identified as prognostic factors for bone metastasis in patients with breast cancer. So patients with these characteristics should be monitored more precisely with regular follow-ups.

Download Full-text

Clinicopathological factors associated with survival in patients with breast cancer brain metastasis

Human Pathology ◽

10.1016/j.humpath.2017.03.022 ◽

2017 ◽

Vol 64 ◽

pp. 53-60 ◽

Cited By ~ 8

Author(s):

Rong Li ◽

Kui Zhang ◽

Gene P. Siegal ◽

Shi Wei

Keyword(s):

Breast Cancer ◽

Brain Metastasis ◽

Clinicopathological Factors ◽

Factors Associated ◽

Breast Cancer Brain Metastasis

Download Full-text

CLINICOPATHOLOGICAL FACTORS ASSOCIATED WITH POSITIVE PREOPERATIVE AXILLARY ULTRASOUND SCANNING IN BREAST CANCER PATIENTS

International Journal of Surgery and Medicine ◽

10.5455/ijsm.breastcancer ◽

2016 ◽

Vol 2 (1) ◽

pp. 23 ◽

Cited By ~ 1

Author(s):

Lona Jalini ◽

Dave Fung ◽

Kaushik Dasgupta ◽

Vijay Kurup

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Clinicopathological Factors ◽

Ultrasound Scanning ◽

Breast Cancer Patients ◽

Axillary Ultrasound ◽

Factors Associated

Download Full-text

Identifying Clinicopathological Factors Associated with Oncotype DX® 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, Canada

Journal of Personalized Medicine ◽

10.3390/jpm11090858 ◽

2021 ◽

Vol 11 (9) ◽

pp. 858

Author(s):

Simon Gagnet ◽

Caroline Diorio ◽

Louise Provencher ◽

Cynthia Mbuya-Bienge ◽

Julie Lapointe ◽

...

Keyword(s):

Breast Cancer ◽

Cohort Study ◽

Retrospective Cohort Study ◽

Retrospective Cohort ◽

Early Stage ◽

Recurrence Score ◽

Histologic Grade ◽

Quebec City ◽

Clinicopathological Factors ◽

Factors Associated

Gene expression profiling tests such as the Oncotype DX (ODX) 21-gene recurrence score (RS) assay is increasingly used in clinical practice to predict the risk of recurrence and support treatment planning for early-stage breast cancer (BC). However, this test has some disadvantages such as a high cost and a long turnaround time to get results, which may lead to disparities in access. We aim to identify clinicopathological factors associated with ODX RS in women with early-stage BC. We conducted a retrospective cohort study of women identified in the medical database of the Deschênes-Fabia Breast Disease Center of Quebec City University, Canada. Our sample consists of 425 women diagnosed with early-stage BC who have obtained an ODX RS between January 2011 and April 2015. The ODX RS has been categorized into three levels as originally defined: low (0–17), intermediate (18–30), and high (>30). The mean RS was 17.8 (SD = 9.2). Univariate analyses and multinomial logistic regressions were performed to identify factors associated with intermediate and high RS compared with low RS. A total of 237 (55.8%) patients had low RS, 148 (34.8%) had intermediate RS, and 40 (9.4%) had high RS. Women with progesterone receptor (PR)-negative (ORs ranging from 3.51 to 10.34) and histologic grade II (ORs ranging from 3.16 to 23.04) tumors were consistently more likely to have intermediate or high RS than low RS. Similar patterns of associations were observed when the RS was categorised using redefined thresholds from (i.e., from the TAILORx study or dichotomized). This study provides evidence suggesting that histologic grade and PR status are predictive factors for intermediate or high RS in women with early-stage BC. If these results are confirmed in future studies, considering these clinicopathological factors could spare women the need to get such a test before the beginning of a possible adjuvant therapy. This option could be considered in settings where the cost of testing is an issue.

Download Full-text